Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.56 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.56 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29559517 | 1.00 | SMN1; SMN2 (0.63) | SMN1; SMN2KDM4EALDH1A1GAAHPGD | |
| SCHEMBL30868870 | 0.79 | KDM4E (0.62) | SMN1; SMN2KDM4EALDH1A1GAAHPGD | |
| SCHEMBL3978504 | 0.79 | KDM4E (0.62) | SMN1; SMN2KDM4EALDH1A1GAAHPGD | |
| SCHEMBL1053419 | 0.78 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4EALDH1A1GAAMAPT | |
| SCHEMBL28091224 | 0.78 | KDM4E (0.60) | SMN1; SMN2KDM4EALDH1A1GAAHPGD | |
| Hydrochloric Acid SCHEMBL31039939 | 0.78 | KDM4E (0.60) | SMN1; SMN2KDM4EALDH1A1GAAHPGD | |
| Hydrochloric Acid SCHEMBL31039933 | 0.78 | KDM4E (0.60) | SMN1; SMN2KDM4EALDH1A1GAAHPGD | |
| SCHEMBL29466906 | 0.78 | KDM4E (0.60) | SMN1; SMN2KDM4EALDH1A1GAAHPGD | |
| SCHEMBL16065981 | 0.78 | SMN1; SMN2 (0.63) | SMN1; SMN2KDM4EALDH1A1GAAMAPT | |
| SCHEMBL5545639 | 0.77 | KDM4E (0.67) | SMN1; SMN2KDM4EALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012085648-A1 | PHOSPHORUS-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2012-06-28 | — | — | WO | disclosed |
| EP-1711184-B1 | (3-OXO-3,4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-18 | — | — | EP | disclosed |
| EP-1711184-B1 | (3-OXO-3,4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-18 | — | — | EP | disclosed |
| EP-1711184-A1 | (3-OXO-3,4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005067932-A1 | (3-OXO-3, 4-DIHYDRO-QUINOXALIN-2-YL-AMINO) -BENZAMIDE DERIVATIVES AND RELATED COMPOUND AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-07-28 | — | — | WO | disclosed |
| US-20050148586-A1 | Quinoxalinones | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-07-07 | — | — | US | disclosed |
| US-4668678-A | ANTIALLERGENS | USV PHARMACEUTICAL CORPORATION (US) | 1987-05-26 | — | — | US | disclosed |
| US-4507300-A | Pyridotriazolopyrazine-diones for treating allergy | USV PHARMACEUTICAL CORPORATION (US) | 1985-03-26 | — | — | US | disclosed |
| EP-0039920-B1 | TRIAZALOQUINOXALIN-1,4-DIONES | USV PHARMACEUTICAL CORPORATION (US) | 1984-07-25 | — | — | EP | disclosed |
| US-4400382-A | Thiazoloquinoxalin-1,4-diones for treating allergy | USV PHARMACEUTICAL CORPORATION (US) | 1983-08-23 | — | — | US | disclosed |
| EP-0039920-A2 | Triazaloquinoxalin-1,4-diones | USV PHARMACEUTICAL CORPORATION (US) | 1981-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148586-A1 | Quinoxalinones | SLC5A2, GPR119, GLS2 | SMN1; SMN2 4347/4885KDM4E 1657/4885ALDH1A1 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.